Novel therapeutic vaccine: Granulysin and new DNA vaccine against tuberculosis

Human Vaccines

Volumn 7, Issue SUPPL., 2011, Pages 60-67

  Okada, Masaji ^a   Kita, Yoko ^a   Nakajima, Toshihiro ^b   Kanamaru, Noriko ^a   Hashimoto, Satomi ^a   Nagasawa, Tetsuji ^b   Kaneda, Yasufumi ^c   Yoshida, Shigeto ^d   Nishida, Yasuko ^a   Nakatani, Hitoshi ^a   Takao, Kyoko ^a   Kishigami, Chie ^a   Nishimatsu, Shiho ^a   Sekine, Yuki ^a   Inoue, Yoshikazu ^a   Matsumoto, Makoto ^e   McMurray, David N ^f   Dela Cruz, E C ^g   Tan, E V ^g   Abalos, R M ^g   Burgos, J A ^g   Saunderson, Paul ^g   Sakatani, Mitsunori ^a   more..

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^b Ikeda Laboratory   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^f TEXAS A AND M UNIVERSITY   (United States)

^g Cebu Skin Clinic   (Philippines)

Author keywords

Cytotoxic T cell; HVJ envelope; IL 2; Monkey granulysin; Mouse; Multi drug resistant tuberculosis; Mycobacterium tuberculosis; Therapeutic vaccine; XDR TB

Indexed keywords

BCG VACCINE; DNA VACCINE; GRANULYSIN; HEAT SHOCK PROTEIN 65 PLUS INTERLEUKIN 12P40P35 DNA VACCINE; INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BCG VACCINATION; BODY WEIGHT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; ERYTHROCYTE SEDIMENTATION RATE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HAPLORHINI; IMMUNE RESPONSE; INFECTION PREVENTION; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; REVIEW; SKIN TEST; THORAX RADIOGRAPHY; VIRAL GENE DELIVERY SYSTEM;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BACTERIAL PROTEINS; CHAPERONIN 60; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; MACACA FASCICULARIS; PRIMATE DISEASES; RODENT DISEASES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUBERCULOSIS VACCINES; TUBERCULOSIS, MULTIDRUG-RESISTANT; VACCINES, DNA;

EID: 84855755517     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.0.14563     Document Type: Review

References (22)

1. Yoshida S, Tanaka T, Kita Y, Kuwayama S, Kaneda Y, Okada M, et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine 2006; 24:1191-204. (Pubitemid 43202265)
2. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomologus monkey model of TB. Vaccine 2007; 25:2990-3. (Pubitemid 46509463)
3. Okada M, Kita Y. Tuberculosis vaccine development; The development of novel (preclinical) DNA vaccine. Human Vaccines 2010; 6:297-308.
4. Walsh GP, Tan EV, dela Cruz EC, Abalos RM, Villahermosa LG, Young LJ, et al. The Philippine cynomolgus monkey provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 1996; 2:430-6. (Pubitemid 26191915)
5. Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 2005; 23:2132-5. (Pubitemid 40341439)
6. Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus). Hum Gene Ther 1997; 8:2133-41.
7. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002; 6:219-26. (Pubitemid 36336129)
8. Kaneda Y. New vector innovation for drug delivery: development of fusigenic non-viral particles. Curr Drug Targets 2003; 4:599-602. (Pubitemid 37236374)
9. Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. Adv Genet 2005; 53:307-32. (Pubitemid 43580672)
10. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005; 7:1044-52. (Pubitemid 41195066)
11. Mima H, Yamamoto S, Ito M, Tomoshige R, Tabata Y, Tamai K, et al. Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol Cancer Ther 2006; 5:1021-8. (Pubitemid 43724603)
12. Okada M, Yoshimura N, Kaieda T, Yamamura Y, Kishimoto T. Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. Proc Natl Acad Sci USA 1981; 78:7717-21. (Pubitemid 12186633)
13. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 2009; 27:3267-70.
14. Okada M, Okuno Y, Hashimoto S, Kita Y, Kanamaru N, Nishida Y, et al. Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models. Vaccine 2007; 25:3038-40. (Pubitemid 46509464)
15. Tanaka F, Abe M, Akiyoshi T, Nomura T, Sugimachi K, Kishimoto T, et al. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. Cancer Res 1997; 57:1335-43. (Pubitemid 27152560)
16. Huygen K. DNA vaccines: application to tuberculosis. Int J Tuberc Lung Dis 1998; 2:971-8. (Pubitemid 29005212)
17. Lowrie DB. DNA vaccines against tuberculosis. Curr Opin Mol Ther 1999; 1:30-3. (Pubitemid 29236615)
18. Hoft D. Tuberculosis vaccine development: goals, immunological design and evaluation. Lancet 2008;372:164-75. (Pubitemid 351952260)
19. Gupta UD, Katoch VM, McMurray DN. Current status of TB vaccines. Vaccine 2007; 25:3742-51. (Pubitemid 46613832)
20. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19:93-129. (Pubitemid 32368031)
21. Rook GAW, Lowrie DB, Hernandez-Pando R. Immunotherapeutics for Tuberculosis on experimental animals: Is there a common pathway activated by effective protocols? J Inf Dis 2007; 196:191-8. (Pubitemid 47047457)
22. Kaufmann SHE. New vaccine for tuberculosis. The Lancet 2010; 375:85-94.